Human Segment has the Largest Share of Source in the Europe Monoclonal Antibodies Market during 2021–2028

According to our latest study on “Europe Monoclonal Antibodies Market Forecast to 2028 – COVID-19 Impact and Analysis – by Source, Production Method, Indication, Application, and End User,” the market is projected to reach US$ 61,019.8 million by 2028 from US$ 29,254.3 million in 2021; it is expected to grow at a CAGR of 11.1% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising prevalence of cancer and other chronic diseases, mABs uptake proves to be effective during pandemic outbreaks. However, low awareness, accessibility, and high cost is expected to restrict the market growth during the forecast period.

The European market is severely hit due to the exponential increase of COVID-19 cases in the region. Many nations are revealing more patients per day now than during the first wave earlier this year. Lockdowns are being reintroduced in UK, Spain, and Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 crises, the government of many nations is heading towards mounting up testing capacity. Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have recorded the most significant number of positive cases and have registered the maximum number of deaths. The rising rate of coronavirus results in increased stress on the region's healthcare system, raising the demand for diagnostic tests in its healthcare system, supporting the expansion of the sector in this region. Moreover, In December 2021, Pfizer and BioNTech announced that the companies will amend the clinical safety study while evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children 6 months to under 5 years of age.

Based on source, the Monoclonal Antibodies (mAbs) market is segmented into human, humanized, chimeric, and murine. In 2020, the human segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 12.7% in the forecast period.

Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., AstraZeneca, Eli Lilly and Company, Bayer AG, and Bristol-Myers Squibb Company are among the leading companies in the Europe monoclonal antibodies market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.

The market for monoclonal antibodies market is segmented into source, production method, indication, application, and end user. Based on source, the Europe monoclonal antibodies market is segmented into human, humanized, chimeric, murine. Based on production method, the monoclonal antibodies market is segmented into in-vitro, in-vivo. Based on indication, the monoclonal antibodies market is segmented into cancer, autoimmune diseases, infectious diseases, inflammatory diseases, microbial diseases, others. Based on application, the monoclonal antibodies market is segmented into therapeutic applications, diagnostic applications, research applications. Based on end user, the monoclonal antibodies market is segmented into hospitals, research institutes, others. Geographically, the monoclonal antibodies market is segmented into Europe (Germany, UK, France, Spain, Italy, Rest of Europe).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com